Key points from article :
German company CorTec has received approval to begin human trials of its Brain Interchange System in the USA. The system, a brain-computer interface designed to aid rehabilitation after a stroke, was granted approval by the Institutional Review Board (IRB) at the University of Washington, where a feasibility study will be conducted. Prior to this, the U.S. Food and Drug Administration (FDA) had already approved the technical safety and study design of the device, marking a significant milestone for the project. CorTec and the research team are now preparing to recruit volunteers for the trial.
The Brain Interchange System is an innovative tool that allows for a seamless exchange of information between the brain and technology. By electrically stimulating specific areas of the brain, the system aims to assist stroke patients with upper limb impairments during their rehabilitation process. CorTec’s device is fully implantable and works on 32 channels, both for sensing and stimulation, making it a promising technology for developing new therapies targeting the central nervous system.
Founded in 2010, CorTec specializes in neurotechnology, providing advanced systems for both clinical and industrial research into new brain therapies. With the approval for human trials, the company hopes to pave the way for more effective treatments for patients recovering from neurological conditions like stroke.
